Day: March 16, 2023

– Q4 revenue up 9% quarter over quarter to $44.3 million – – FY 2022 cash from operations up significantly to $8.6 million, compared to cash used of $8.6 million in FY 2021 – – Recently completed refinancing of legacy debt, reducing principal debt outstanding by nearly half – PHOENIX, March 16, 2023 (GLOBE NEWSWIRE) — TILT Holdings Inc. (“TILT” or the “Company”) (NEO:TILT) (OTCQX: TLLTF), a global provider of cannabis business solutions that include inhalation technologies, cultivation, manufacturing, processing, brand development and retail, is reporting its financial and operating results for the three and twelve months ended December 31, 2022. All financial information is reported in U.S. dollars and prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”)...

Completes Integration, Validates Breakthrough Technologies, Proves Commercial Readiness of Technologies VIRGINIA CITY, Nev., March 16, 2023 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”), an innovator of technologies that enable systemic decarbonization, today announced its full year 2022 results, summary of achievements completed in 2022, and our 2023 business outlook. “During 2022, we integrated our acquisitions, achieved extraordinary technological breakthroughs, advanced each business, and monetized non-strategic assets,” said Corrado De Gasperis, Comstock’s executive chairman and chief executive officer. Selected Strategic Highlights from 2022 The following is a selection of strategic highlights from the year: Cellulosic Fuels “Our renewable fuels team recently demonstrated commercial readiness...

Conference call and live webcast at 4:30 p.m. ET today NEWTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) — Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced financial results for the twelve months ended December 31, 2022, and provided a business update. Highlights for the fourth quarter of 2022 and recent weeks include:Based upon encouraging safety findings from its ongoing Phase 1 program, Onconova intends to administer narazaciclib orally with a continuous daily dosing schedule in upcoming clinical trials. Results from the Phase 1 solid tumor trial evaluating a continuous daily dosing regimen of narazaciclib showed that the maximum tolerated dose was not reached through the fifth dose...

Conference call and webcast today at 4:30 p.m. ET NEWARK, Calif., March 16, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year and fourth quarter ended December 31, 2022. Sujal Shah, President and CEO of CymaBay, stated, “We are off to a fast start in 2023 after making significant progress in 2022 in our development program evaluating seladelpar for patients with primary biliary cholangitis (PBC). Since completing enrollment in RESPONSE, our global phase 3 registration study, in July 2022, we presented data at The Liver MeetingÒ, licensed rights to develop and commercialize seladelpar for patients with PBC in Japan...

Announces Strategic Restructuring and Elimination of $15 Million of Costs; Simplifying Core Business Around Playboy and Honey Birdette LOS ANGELES, March 16, 2023 (GLOBE NEWSWIRE) — PLBY Group, Inc. (NASDAQ: PLBY) (“PLBY Group” or the “Company”), a leading pleasure and leisure lifestyle company and owner of Playboy, one of the most recognizable and iconic brands in the world, today provided financial results for the fourth quarter and full year ended December 31, 2022. Comments from Ben Kohn, Chief Executive Officer of PLBY Group “Last year was challenging on a number of fronts. We embarked on a strategic review to restructure and simplify our business. We have reduced leverage and are evolving our strategy to move to a capital light model entirely focused on our most valuable brands, Playboy and Honey Birdette. This restructuring...

Clinical updates on track for NKX101 in first half of 2023 and NKX019 in full year 2023 2022 year-end cash and cash equivalents of $354.9 million Cash runway anticipated to fund operations into 2025SOUTH SAN FRANCISCO, Calif., March 16, 2023 (GLOBE NEWSWIRE) — Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2022. “Clinical data from our co-lead pipeline candidates have highlighted the promise of our allogeneic NK cell therapy technology to lead the next wave of cell therapy,” said Paul J. Hastings, President and CEO of Nkarta. “We believe that the future of cell therapy is improved accessibility, and NK cells may be uniquely equipped to overcome...

Q4 2022 revenue of $8.5 million Q4 Product sales and royalty revenue up 220% from prior year and 9% from Q3 Q4 positive net income Management to hold conference call today at 4:30pm ETDEER PARK, Ill., March 16, 2023 (GLOBE NEWSWIRE) — Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2022. “The fourth quarter was another impressive quarter for Eton, fueled by the continued momentum of ALKINDI SPRINKLE and Carglumic Acid. It was our eighth straight quarter of sequential revenue growth in product and royalty revenue, and we expect that strong growth to continue throughout 2023 and beyond,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “Our...

CARLSBAD, Calif., March 16, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today reported results for the fourth quarter and full year ended December 31, 2022. Financial statements and other information presented for 2022 is unaudited. Recent Highlights:Reported revenue of $5.0 million for the fourth quarter of 2022, a 14% increase compared to $4.4 million for the same quarter last year Reported revenue of $16.4 million for the full year of 2022, a 5% decrease compared to $17.3 million for the full year of 2021 Global mapping procedure volumes increased 19% for the full year of 2022, compared to the full year of 2021 Achieved key milestones under the asset purchase agreement with...

VEON publishes preliminary 4Q22 and FY22 results Sale of Russia will lead to a significant reduction in debt Amsterdam, 16 March 2022: A correction has been issued for the release disseminated today at 07:00 CET.  The figure for EBITDA in FY 2022 highlights was inaccurately cited. The correct amount is USD 1,743 million. The complete and corrected release follows: Amsterdam, 16 March 2022 07:00 CET: VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, announces selected financial and operating results for the fourth quarter and full year ended 31 December 2022, excluding the results of the Russian operations, as they were classified as ‘held for sale’ and ‘discontinued operations’ in 4Q22: In Q4 2022, VEON’s local currency performance accelerated sharply...